导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.17% | 4097/4773 |
| 近一周 | -2.43% | 2138/5462 |
| 近一月 | -2.44% | 1270/5421 |
| 近一季 | -5.45% | 1848/5209 |
| 近半年 | -11.89% | 3746/4920 |
| 近一年 | -15.35% | 3692/4366 |
| 近两年 | 18.43% | 2674/2954 |
| 近三年 | 10.75% | 1726/2253 |
| 成立以来 | 6.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.16% 4261/4961 |
-7.17% 3772/5312 |
- - |
- - |
| 2025 | 10.50% 2806/4813 |
4.87% 869/3635 |
-4.26% 3466/4076 |
12.98% 3025/4524 |
-2.59% 3175/4813 |
| 2024 | 25.09% 271/3463 |
5.26% 383/2808 |
-1.31% 1033/3014 |
17.28% 1217/3129 |
2.68% 907/3463 |
| 2023 | -5.57% 753/2656 |
3.30% 1220/2280 |
-1.21% 453/2385 |
-1.85% 588/2515 |
-5.72% 1477/2655 |
| 2022 | -16.88% 527/2207 |
-18.37% 1326/1919 |
16.12% 156/2016 |
-14.14% 1031/2113 |
2.13% 1031/2208 |
| 2021 | 0.39% 714/1822 |
-2.15% 588/1255 |
3.86% 947/1330 |
-7.07% 1018/1466 |
6.29% 220/1822 |
| 2020 | 36.61% 391/1250 |
-9.73% 716/1028 |
16.96% 402/1067 |
14.99% 245/1164 |
12.52% 458/1184 |
| 2019 | 29.49% 502/1092 |
24.63% 497/754 |
-6.41% 506/804 |
1.87% 349/850 |
8.98% 265/918 |
| 2018 | -31.62% 501/834 |
- - |
- - |
- - |
-11.82% 355/691 |
| 2017 | 4.63% 389/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.35% 358/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发中证全指可选消费联接A VS. 长安沪深300非周期A(740101) |